Drug programs fail more often than they succeed. When one falters, people usually assume it was because the science didn’t pan out. Sometimes, that’s the right explanation.
Examine enough of these programs more closely, and another picture comes into focus. Toxicology findings didn’t reach regulatory planning in time. Manufacturing decisions were made in isolation, before anyone thought through what they would mean for clinical operations. Teams were operating on different assumptions. The science, in many of these cases, worked fine. The problem was that no one was responsible for how all of it fit together.
Drug development is a process that stretches across years, continents and specialized disciplines. Yet most programs have no single person accountable for how all of the pieces connect and translate. Each team does its own work well, and the gaps between them are where timelines slip, budgets grow and programs lose momentum.
The general contractor gap
A clear and relatable analogy is the process of building a house.
When you do, you hire an electrician, a plumber, a framing crew and a dozen other specialists. They all know their trade, but none of them is responsible for anyone else’s work. Things get missed, costs pile up and problems that would have been easy to fix early become expensive headaches. That’s why general contractors exist. They own the timeline, sequence the trades, catch problems before they cascade and make sure the house actually gets built smoothly and efficiently.
Drug development, despite its far higher stakes, often tries to get by without anyone playing that role. Biotech companies either lean on internal teams already stretched too thin or bring in consultants who produce sharp strategic recommendations and then move on to the next engagement. Either way, the daily work of keeping everything connected falls to no one. So it doesn’t happen, or it happens too late.
Driving the program forward
KreaMedica fills that general contractor role for biotech companies from early planning through regulatory submission. We don’t just advise—we take ownership of execution. Our team is embedded in the program, tracking progress in real time, flagging risks and keeping every function aligned with where it’s headed.
When a program requires highly specialized expertise, we bring in the right experts through our vetted specialist network, KreaConnect – Think of them as the architects. As the general contractor we stay responsible for the delivery, but critical decisions demand a true subject matter expert; someone who is trusted and has spent years in that specific discipline. A CMC specialist engaged during process development can make decisions that hold up under regulatory scrutiny. That same expert, brought in too late, when poor decisions were already made, is often left mitigating issues that could have been avoided in the first place. Bring in expertise for design—not for damage control.
Keeping it all together
Biotech has scientific talent and ambition. The operational side just doesn’t get the same attention. Promising programs lose time and money to vendor miscommunications, regulatory strategies that were never pressure-tested, and manufacturing choices that no one revisited until it was too late. With KreaMedica, you have a partner who takes ownership of the full program—so you can stay focused on advancing the science.
Watch the video to see how this comes together in practice: